These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20408071)

  • 1. Accuracy and precision of intravitreally injected ranibizumab doses: an experimental study.
    Gerding H; Timmermann M
    Klin Monbl Augenheilkd; 2010 Apr; 227(4):269-72. PubMed ID: 20408071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
    Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
    Rosenfeld PJ; Schwartz SD; Blumenkranz MS; Miller JW; Haller JA; Reimann JD; Greene WL; Shams N
    Ophthalmology; 2005 Jun; 112(6):1048-53. PubMed ID: 15885778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy and precision of low-dose insulin administration.
    Casella SJ; Mongilio MK; Plotnick LP; Hesterberg MP; Long CA
    Pediatrics; 1993 Jun; 91(6):1155-7. PubMed ID: 8502520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring ocular drug therapy by analysis of aqueous samples.
    Campochiaro PA; Choy DF; Do DV; Hafiz G; Shah SM; Nguyen QD; Rubio R; Arron JR
    Ophthalmology; 2009 Nov; 116(11):2158-64. PubMed ID: 19700195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
    Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
    Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab.
    Theoulakis PE; Lepidas J; Petropoulos IK; Livieratou A; Brinkmann CK; Katsimpris JM
    Klin Monbl Augenheilkd; 2010 Apr; 227(4):280-4. PubMed ID: 20408074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.
    Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL
    Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure.
    Gismondi M; Salati C; Salvetat ML; Zeppieri M; Brusini P
    J Glaucoma; 2009 Dec; 18(9):658-61. PubMed ID: 20010243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Bhatnagar P; Spaide RF; Takahashi BS; Peragallo JH; Freund KB; Klancnik JM; Cooney MJ; Slakter JS; Sorenson JA; Yannuzzi LA
    Retina; 2007 Sep; 27(7):846-50. PubMed ID: 17891007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of intravitreally and intraperitoneally injected atropine on two types of experimental myopia in chicken.
    Diether S; Schaeffel F; Lambrou GN; Fritsch C; Trendelenburg AU
    Exp Eye Res; 2007 Feb; 84(2):266-74. PubMed ID: 17101130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The first experience of intravitreal injection of Lucentis (ranibizumab) in the moist form of age-related maculodystrophy].
    Baĭborodov IaV
    Vestn Oftalmol; 2009; 125(5):31-3. PubMed ID: 19916331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of SoloShot autodestruct syringes compared with disposable syringes, in a national immunization campaign in Indonesia.
    Nelson CM; Sutanto A; Suradana IG
    Bull World Health Organ; 1999; 77(1):29-33. PubMed ID: 10063658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
    Gaudreault J; Fei D; Rusit J; Suboc P; Shiu V
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):726-33. PubMed ID: 15671306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative technique for reducing compound waste during intravitreal injections.
    Ribeiro JA; Messias A; Scott IU; Jorge R
    Arq Bras Oftalmol; 2009; 72(5):641-4. PubMed ID: 20027401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
    Regillo CD; Brown DM; Abraham P; Yue H; Ianchulev T; Schneider S; Shams N
    Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
    Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.